Cedars-Sinai Medical Center

medical staff pulse newsletter

Text size: A A A

December P&T decisions released

Pharmacy Focus

December Pharmacy and Therapeutics Committee decisions and pertinent agenda topics are summarized in the PDF file below. Highlights include: updated C. diff treatment guidelines, dabigatran safety analysis, nesiritide guidelines, and risk evaluation and mitigation strategies for rosiglitazone and dofetilide.

P&T Approvals: December 2011 (PDF)

Meetings and Events

Grand Rounds

Click here to view upcoming Grand Rounds.

Upcoming CME Conferences

Click below to view a complete list of all scheduled Continuing Medical Education conferences.

CME Newsletter - January 2012 (PDF)

Share Your News

Won any awards or had an article accepted for publication? Share your news about professional achievements and other items of interest.

Click here to share your news

Cedars-Sinai Husband-Wife Team Launching Experimental Therapeutics Program in Cancer

Based in a quiet corner of Cedars-Sinai's Saperstein Critical Care Tower, new faculty members Alain and Monica Mita are launching a program for the Samuel Oschin Comprehensive Cancer Institute to test cutting-edge cancer treatments. Their work is expected to benefit not only the medical center's researchers and physicians but, most importantly, the patients.

Cedars-Sinai's new Experimental Therapeutics program, co-directed by the Mitas, who are both MDs and distinguished scientists, so far consists of a state-of-the-art Clinical Research Unit with six treatment rooms on the restricted-access mezzanine of the Saperstein Tower. Patients are just starting to trickle in.

But the Mitas have big plans.

"We hope to build a world-class program," Alain said. "We're going to work with patients who have no more treatment options and find them treatments."

Monica said they also will help patients "where we feel we can offer a novel treatment that might be better" than existing options.

In either case, she said, "we would like our work to be a collaboration with other departments," with clinical physicians referring patients for treatments that will generate research findings that may be applied to future patients. They also envision collaborating with eminent laboratory researchers at Cedars-Sinai to further refine the understanding of the novel anti-cancer therapies under investigation in the Experimental Therapeutics unit.

The Mitas arrived at Cedars-Sinai in September from San Antonio, where they held parallel posts as associate professors of medicine at the University of Texas Health Science Center and staff medical oncologists at the NCI-designated Cancer Therapy and Research Center.

At the Cancer Therapy and Research Center's Institute for Drug Development, Alain was principal investigator, and Monica was clinical research director and principal investigator.

Earlier, the Mitas had spent a decade in France pursuing postgraduate studies and postdoctoral medical training after leaving their native Romania following the 1989 fall of Communist dictator Nicolae Ceausescu. ("We were disappointed it was not a true regime change to democracy," Alain said.)

At Cedars-Sinai, the couple is taking on the task of creating a program at "one of the premier cancer centers," Alain said.

"Our passion is the development of new drugs for cancer therapy," he said.

Alain's specialties include lung cancer and thoracic malignancies; Monica focuses on breast cancer and sarcomas. But their research findings can be applied to many types of malignancies.

Alain, for instance, was the principal investigator for early Phase I trials of cabazitaxel, a high-potency chemotherapy that the U.S. Food and Drug Administration approved in 2010 for treatment of prostate cancer. In December, Monica initiated a study exploring the application of iniparib, a PARP-inhibitor that has been used against breast cancer, to other types of tumors.

On Jan. 16, the couple plans to open the Clinical Research Unit after holding an open house Jan. 13

"We are very excited about this opportunity," Monica said.